看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
* m1 S/ ^$ O& b$ B) x2 C+ U3 w9 m1 `" b7 b6 G5 T; J3 \
& j: T4 V6 d: U& V! Y5 D1 VCurrently available feasibility data for possible combination strategies. ( \# c& Q( v6 P3 ] F: k# L* m5 G
————————————————————————————————
) U% a1 a5 \( |; D1 h4 ~" Z4 u6 iCombination Feasibility according to preliminary data 5 S: U7 I, f- T
——————————————————————————————————
4 S3 T* F" H6 QBevacizumab + sorafenib Yes, reduced dose
/ q& Z/ ?3 p# v# [! `% ^Bevacizumab + sunitinib† No
5 Q: K4 d4 I5 n& S! x) K$ c) T& @Bevacizumab + temsirolimus Yes
. w0 I Y% d# I9 cBevacizumab + everolimus Yes
# w y$ i3 B/ wSorafenib + sunitinib ?
7 T9 g" J; U7 jSorafenib + temsirolimus Yes, reduced dose
& U! t, C7 D& T" Q* Z' OSorafenib + everolimus Yes, reduced dose 4 d# C+ I0 y8 S6 D! b: p0 z% c
Sunitinib + temsirolimus† No
5 }. T3 G& x) Y+ SSunitinib + everolimus ?
4 t$ w+ \5 }( J" ATemsirolimus + everolimus ?
* Y- ?' Z: F! F) r————————————————————
3 e; F3 N' }- W5 G4 G†Led to US FDA warning.) j' J) Y# ~+ i+ F0 u5 G
?: As yet unattempted combination.( w& Q w: m. h7 s2 B/ {
|